Brief: BriaCell Provides Phase 3 Clinical Engagement Update In Metastatic Breast Cancer Pivotal Study
15/10/2024 13:06
Oct 15 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* BRIACELL PROVIDES PHASE 3 CLINICAL ENGAGEMENT UPDATE IN
METASTATIC BREAST CANCER PIVOTAL STUDY
* BRIACELL THERAPEUTICS CORP: PHASE 3 STUDY PATIENT
ENROLLMENT
COMPLETION FOR METASTATIC BREAST CANCER PIVOTAL STUDY IS
EXPECTED IN MID-2025
Source text for Eikon: ID:nGNX3dXbj6
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study